2025.07. 28 本文字数：804，阅读时长大约2分钟 7月28日，A股三大指数全天震荡反弹，截至收盘，沪指涨0.12%，深证成指涨0.44%；创业板指涨 0.96%，再创年内新高。 作者 | 一财资讯 具体来看，PCB概念股爆发，大族数控、方邦股份、芯碁微装等10股涨停。 影视院线板块全天强势，幸福蓝海、中国电影涨停，上海电影涨超9%，横店影视、华谊兄弟等跟涨。 煤炭、钢铁等资源股调整，柳钢股份、西宁特钢、山西焦煤、郑州煤电等跌超5%。 | 代码 名称 | | 张幅金 | 现价 | 代码 名称 | 涨幅� | 现价 | | --- | --- | --- | --- | --- | --- | --- | | 600121 郑州煤电 | | -6.37% | 4.26 | 600117 西宁特钢 | -8.68% | 3.47 | | 000983 山西集煤 | | -6.05% | 7.30 | 601003 柳钢股份 | -8.58% | 6.71 | | 600397 安源煤业 | | -5.47% | 6.22 | 600295 鄂尔多斯 | -6.42% | 9.92 | | 601015 ...

沪深两市全天成交额1.74万亿，较上个交易日缩量450亿。全市场超2700只个股上涨。 盘面上，PCB概念、兵装重组板块涨幅居前，算力硬件股午后走强，创新药概念表现活跃，钢铁、煤炭等周期股集体调整。 具体来看，PCB概念股爆发，大族数控、方邦股份、芯碁微装等10股涨停。 影视院线板块全天强势，幸福蓝海、中国电影涨停，上海电影涨超9%，横店影视、华谊兄弟等跟涨。 煤炭、钢铁等资源股调整，柳钢股份、西宁特钢、山西焦煤、郑州煤电等跌超5%。 | 代码 名称 | 涨幅↑ | 现价 | 代码 名称 | 涨幅↑ | 现价 | | --- | --- | --- | --- | --- | --- | | 600121 郑州煤电 | -6.37% | 4.26 | 600117 西宁特钢 | -8.68% | 3.47 | | 000983 山西焦煤 | -6.05% | 7.30 | 601003 柳钢股份 | -8.58% | 6.71 | | 600397 安源煤业 | -5.47% | 6.22 | 600295 鄂尔多斯 | -6.42% | 9.92 | | 601015 陕西黑海 | -5.33% | 3.7 ...

Market Overview - The Hang Seng Index (HSI) opened up 70 points and peaked at nearly 300 points before retracting gains, closing up 0.40% at 25,490.45 points [1] - The Hang Seng Tech Index fell by 0.59%, closing at 5,644.52 points [1] - Total market turnover reached HKD 149.725 billion [1] Sector Performance - The financial sector, including Chinese securities firms and insurance companies, showed strong performance [1] - Innovative drug concepts also performed well, contributing to the overall market gains [1] - Conversely, sectors such as coal and non-ferrous metals experienced declines [1] Notable Stocks - China Tobacco Hong Kong (06055.HK) surged by 13.78% after reaching an agreement with China Tobacco International to maintain its position in the domestic duty-free cigarette business [1] - China Ping An (02318.HK) increased by 3.21% [1] - Hengrui Medicine (01276.HK) rose by 15.43% [1] - China Shenhua (01088.HK) saw a decline of 1.85% [1]

固定收益 | 固定收益专题 基金转债持仓分析 证券研究报告 25Q2，类底仓转债方向分化 2025Q2 公募基金转债持仓概览 2025Q2，权益市场延续旺势，债市震荡，股票及混合型基金业绩整体亮 眼，纯债型基金业绩偏弱；权益指数类基金份额微增，纯债型及被动指数 型债基份额明显上升。公募基金"落袋为安"情绪浓厚，持有股债主流资 产市值占比下降，持债市值环比上涨 7.69%至 21.21 万亿元，债券仓位占 比 57.79%，环比下降 0.40pct。 伴随转债赎回潮，2025Q2 公募基金持有转债市值环比继续微降，但转债 参与度继续上升。全市场持有转债的公募基金数量在 25Q2 末降至 2229 只，与 23Q3 持平；持有转债市值占存续转债余额衡量的比例环比提升 0.81pct 至 41.65%，由转债价格上涨和转债市场缩量共同驱动。 2025Q2，二级债基继续减仓转债，一级债基持有转债市值创历史新高。 2025Q2 持有转债市值环比下降 8.66%至 858.67 亿元，为 2021Q4 以 来最低水平；一级债基持有转债市值环比大幅增长 9.26%至 726.56 亿 元，创历史新高；转债基金持有转债市值环 ...

Group 1 - The core viewpoint of the articles highlights the increasing activity in the innovative drug sector, driven by favorable government policies and the introduction of a commercial health insurance directory for innovative drugs [1][2] - Since 2025, the government has proposed multiple policies to optimize drug procurement and support innovative drugs, indicating a positive policy environment for the pharmaceutical industry [1] - The 11th batch of national drug procurement is underway, with expectations for optimized rules and price reductions, moving away from a focus on minimum pricing to a more quality-controlled approach [1] Group 2 - Ever since the 14th Five-Year Plan, a total of 402 new drugs have been included in the medical insurance directory, with innovative drug spending projected to reach 3.9 times that of 2020 by 2024, reflecting a 40% annual growth rate [2] - The establishment of a commercial health insurance directory for innovative drugs will provide a supplementary payment channel for drugs not included in the national medical insurance directory, with over 100 drugs already submitted for approval [2] - The precise adjustment of medical insurance policies is reshaping the pharmaceutical industry ecosystem, transitioning from price wars to value wars, and clearing out low-quality production capacity to create market space for high-quality enterprises [2]

Group 1 - The core viewpoint of the article highlights the active performance of innovative drug concept stocks, with notable gains in specific companies [1] - Yabao Pharmaceutical (600351) reached the daily limit increase, indicating strong market interest and investor confidence [1] - Key technologies saw a rise of over 7%, reflecting positive sentiment in the sector [1] Group 2 - Chengdu Xian Dao, Watson Bio (300142), and Shanghai Kaibao (300039) also experienced upward movement, suggesting a broader trend in the innovative drug industry [1]

Market Overview - The market experienced strong fluctuations throughout the day, with all three major indices reaching new highs for the year. The total trading volume was 1.93 trillion [1] - The concept stocks related to the Yajiang Hydropower Station continued to surge, with companies like China Energy Engineering, China Power Construction, and China Communications Construction hitting the daily limit [1][3] - The coal sector saw significant gains in the afternoon, with companies such as Lu'an Environmental Energy, Jinkong Coal Industry, and Shanxi Coal International also reaching the daily limit [1][6] - In contrast, the innovative drug sector faced a pullback, with Shuyitai falling over 8% [1] Hot Topics Yajiang Hydropower Station Concept - The Yajiang Hydropower Station concept stocks remained strong, with China Power Construction and China Energy Engineering continuing to hit the daily limit, alongside companies like Nankuang Group and Huajian Group achieving three consecutive limits [3] - The total investment for the Yarlung Tsangpo River hydropower project is estimated to exceed 1.2 trillion, significantly higher than many major infrastructure projects in China [4][19] - The construction process for hydropower projects includes various stages such as cofferdam construction, diversion works, and dam construction, which are expected to drive demand for related equipment [4] Coal Sector - The coal sector collectively surged in the afternoon, with Lu'an Environmental Energy, Jinkong Coal Industry, and Shanxi Coal International all hitting the daily limit [6][7] - Recent expectations of a "de-involution" trend have strengthened, leading to a bullish outlook on coal prices, especially with the peak coal consumption season approaching [8] - Insurance capital is expected to overflow into coal dividend stocks due to increasing premiums and policy-driven asset allocation [8] Solid-State Battery Sector - The solid-state battery sector saw a recovery, with companies like Dexin Technology and Haopeng Technology hitting the daily limit, while Xianhui Technology rose over 15% [9][10] - The chairman of Hive Energy announced plans to trial production of semi-solid-state batteries by the fourth quarter of 2025 [10] - The semi-solid-state battery technology is viewed as a suitable transitional solution, with a projected domestic installation volume of 2.2 GWh in the first half of 2024 [10] Other Active Sectors - Other sectors such as photovoltaic, military industry, and robotics showed localized activity, while consumer goods and pharmaceuticals experienced notable declines [11]

Core Viewpoint - The A-share market has shown strong performance recently, with significant gains in the coal sector following a favorable policy announcement aimed at stabilizing coal supply [2][3]. Group 1: Market Performance - On July 22, a favorable policy was announced, leading to a surge in the coal sector, with many stocks hitting the daily limit [3]. - The market experienced fluctuations but ultimately closed higher, with the Shanghai Composite Index rising by 0.62%, the Shenzhen Component by 0.84%, and the ChiNext by 0.61% [9]. - A total of 2,540 stocks rose, with 112 stocks hitting the daily limit, while 2,724 stocks declined [10][11]. Group 2: Policy Impact - The newly introduced "anti-involution" policy aims to regulate coal production, mandating that annual coal output does not exceed announced capacity and monthly output does not exceed 10% of the announced capacity [3]. - This policy is likened to previous supply-side reforms, which significantly influenced coal prices and market performance [7]. - Historical data shows that coal prices have dropped from a peak of 1,202 CNY/ton in 2021 to 658 CNY/ton, a decrease of 45.3% [7]. Group 3: Sector Analysis - Analysts from Zheshang Securities suggest that the "anti-involution" policy could reverse the coal industry's challenges, similar to past supply-side reforms that led to significant price recoveries [7]. - Long-term coal price improvements are anticipated if demand-side improvements follow, particularly with potential interest rate cuts and domestic stimulus [8]. - The demand for coking coal is expected to rise due to high steel mill profits, which are correlated with increased production and operational rates [8].

Group 1 - The innovative drug concept is leading a resurgence in the pharmaceutical market, with companies like Lizhu Group and Borui Pharmaceutical experiencing significant stock price increases [1][3] - The National Healthcare Security Administration (NHSA) recently held a meeting focusing on the comprehensive value assessment of innovative drugs and medical devices, indicating ongoing support for innovation in the sector [3] - A report from CITIC Securities highlights that the NHSA is promoting a shift from low-price competition to quality competition, which is expected to benefit companies with strict quality systems and cost advantages [3] Group 2 - The first drug-focused ETF in China (562050) is gaining attention, concentrating on the top 50 pharmaceutical companies, particularly those involved in innovative drugs and traditional Chinese medicine [4] - The report anticipates that over 90% of innovative drugs will succeed in the 2024 healthcare negotiations, with domestic products accounting for over 70% of that success [3] - The domestic innovative drug companies are expected to enhance their international competitiveness, driven by new technologies and supportive policies [3]

Core Viewpoint - The innovative drug concept stocks have shown significant activity, with Chengdu Xian Dao and Chengda Pharmaceutical both rising over 10% following a meeting by the National Medical Insurance Administration regarding the evaluation of innovative drugs and medical devices [1] Group 1: Stock Performance - Chengdu Xian Dao and Chengda Pharmaceutical both experienced stock increases exceeding 10% [1] - Other companies such as Bai Ao Tai, Sai Sheng Pharmaceutical, Li Zhu Group, Hai Te Biological, Chen Xin Pharmaceutical, and Jian Kang Yuan saw stock rises of over 5% [1] Group 2: Regulatory Developments - The National Medical Insurance Administration held the first session of a series of discussions focused on supporting innovative drugs and medical devices [1] - The discussions centered on the topic of conducting comprehensive value assessments for innovative drugs and medical devices [1]